Development and comparison of three 89Zr-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer: a preclinical study-Reference-Cited by-同舟云学术

Development and comparison of three 89Zr-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer: a preclinical study

Published:2022-03-26 Issue:8 Volume:49 Page:2634-2644
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Hu Guilan,Zhu Wenjia,Liu Yu,Wang Yuan,Zhang Zheng,Zhu Shikun,Duan Wenwen,Zhou Peipei,Fu Chao,Li Fang,Huo Li^ORCID

Funder

National Key Research and Development Program of China

CAMS initiative for Rare Diseases Research Program

Innovative Research Group Project of the National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00259-022-05739-3.pdf

Reference32 articles.

1. Bouché O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study–FFCD 9803. J Clin Oncol. 2004;22:4319–28. https://doi.org/10.1200/jco.2004.01.140.

2. Pozzo C, Barone C, Szanto J, Padi E, Peschel C, Bükki J, et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol. 2004;15:1773–81. https://doi.org/10.1093/annonc/mdh473.

3. Swisshelm K, Macek R, Kubbies M. Role of claudins in tumorigenesis. Adv Drug Deliv Rev. 2005;57:919–28. https://doi.org/10.1016/j.addr.2005.01.006.

4. Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G, Seitz G, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14:7624–34. https://doi.org/10.1158/1078-0432.Ccr-08-1547.

5. Singh P, Toom S, Huang Y. Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer. J Hematol Oncol. 2017;10:105. https://doi.org/10.1186/s13045-017-0473-4.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single-Domain Antibodies as Antibody–Drug Conjugates: From Promise to Practice—A Systematic Review;Cancers;2024-07-27

2. Claudin18.2-Targeted SPECT/CT Imaging for Gastric Cancer: Preclinical Evaluation and Clinical Translation of the ^99mTc-Labeled Nanobody (PHG102) Radiotracer;ACS Pharmacology & Translational Science;2024-07-20

3. Preparation of Radiolabeled Zolbetuximab Targeting CLDN18.2 and Its Preliminary Evaluation for Potential Clinical Applications;Molecular Pharmaceutics;2024-07-01

4. Synthesis, preclinical evaluation and pilot clinical translation of [68Ga]Ga-PMD22, a novel nanobody PET probe targeting CLDN18.2 of gastrointestinal cancer;European Journal of Nuclear Medicine and Molecular Imaging;2024-06-27

5. Recent Advances in Radiotracers Targeting Novel Cancer-Specific Biomarkers in China: A Brief Overview;Journal of Nuclear Medicine;2024-05